Key points are not available for this paper at this time.
Basic NO pathway mapping in vitro warrants clinical caution; leaves open targeted vascular therapies pending validation.
Arginine NO-hydroxylase N&-Hydroxyarginine mono-oxygenase NADPH diaphorase Cytochrome c reductase NADPH oxidase 5 Dihydropteridine reductase Arg + NADPH + H+ + 02 -+ HydroxyArg + NADP+ + H20 HydroxyArg + 1(NADPH + H+) + 02 -+ Cit + NO + H20 NitroBlue Tetrazolium (NBT) + NADPH + H+ Reduced NBT + NADP+ Cyt c+ NADPH + H+ -+ Reduced cyt c+ NADP+ NADPH + H+ + 02 H202 + NADP+ 1NADPH + 02 -+ 02 + 1(NADP+
No takes yet. Share an insight, caveat, or question.
Knowles et al. (1994) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: